In response to She et al., “Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater”

Min Huang, Ralph P. Insinga, Thomas Burke, Ying Zhang, Gilberto de Lima Lopes

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)385-386
Number of pages2
JournalLung Cancer
Volume146
DOIs
StatePublished - Aug 2020

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this